Objective: To compare the effectiveness of Fisher and Paykel (FP) and Vapotherm (VT) high-flow nasal cannula (HFNC) in preventing reintubation either within 72 h or <7 days after extubation of premature infants. The primary outcome was the rate of extubation failure defined as reintubation within 72 h. Secondary outcomes included reintubation after p7 days.
Introduction
Humidified high-flow nasal cannula (HFNC) is a commonly used mode of respiratory support for premature infants in the neonatal intensive care unit (NICU) because of its relative ease of use and perceived comfort to the infant. Heated and humidified gas delivered at high flows (X1 l min -1 ) prevents the heat loss and drying of respiratory mucosa compared with non-humidified heated gas at these flow rates. [1] [2] [3] The gas is heated to near body temperature and humidified at high flow providing 1 to 8 l min -1 of flow in the neonatal population.
HFNC has been shown to improve extubation success when compared with nasal continuous positive airway pressure (CPAP) in premature infants. 4, 5 In addition, Saslow et al. 6 have shown that work of breathing parameters in preterm infants did not differ between HFNC and CPAP. These encouraging observations have led to more frequent use of HFNC in premature infants. Two of the HFNC used in neonates are manufactured by Fisher and Paykel Healthcare (Irvine, CA, USA) and Vapotherm (Stevensville, MD, USA). The mechanics of each model differ somewhat but both provide heated humidified high-flow gas to the infant at close to 100% humidity. However, there is a significant cost differential, which may have important implications given the current economic situation, particularly as it relates to health care (Table 1) . Thus, the objective of this study was to compare the effectiveness of two HFNCs currently available in preventing reintubation either within 72 h, or <7 days after extubation of premature infants.
Methods
This was a prospective, randomized pilot study conducted at the NICU of Crouse Hospital from July 2007 through December 2008. The institutional review board at Crouse Hospital approved the study, and informed written consent was obtained from a parent before each infant was enrolled. Infants were included in the study if they were intubated in the first 72 h of life, were appropriately grown for their gestational age at birth and were born between 26 to 29 completed weeks of gestation. This group of infants was chosen because they are most likely to require the ventilator for a short period of time, and are likely to need respiratory support after extubation. Exclusion criteria included congenital airway anomalies and pulmonary hypoplasia.
The planned enrollment was for 40 infants to ensure that the pilot study could be completed in 1 year. Infants were loaded with 20 mg kg -1 of caffeine citrate before extubation, and they were randomized to either Fisher and Paykel MR850 (FP) or Vapotherm 2000i (VT) HFNC at 6 l/min -1 . They were treated with 5 to 6 mg kg -1 day -1 of maintenance caffeine citrate throughout the study period. Basic health information regarding the pregnancy and neonatal course was obtained from the infant's medical record.
The outer diameter of FP is 2.4 to 2.7 mm, and that of VT is 2.5 to 2.8 mm. Infants were fitted with nasal cannula based on size of the nares with room for nasal flow leakage as recommended by each manufacturer's usage manual. They were extubated directly to FP or VT and weaned by no more than 1 l min -1 in a 24-h period if they met the following criteria: CO 2 of <45 as determined by arterial or capillary blood gas or by transcutaneous (tCO 2 ) monitor, and an oxygen requirement of <30%. If at any time an infant showed signs of respiratory distress after weaning, the attending neonatologist would increase the flow to a maximum of 6 l min -1 . The decision to reintubate was made by the attending neonatologist based on the after criteria: oxygen requirement persistently of >70%, CO 2 level on arterial blood gas sample of >65 combined with a pH of <7.25, >3 apnea episodes requiring moderate stimulation in 12 h or two apnea episodes requiring vigorous stimulation in an 8-h period.
The primary outcome was the rate of extubation failure defined as reintubation within 72 h. Other outcomes that were analyzed included reintubation after p7 days, duration of mechanical ventilation after initial extubation and incidence of chronic lung disease defined as oxygen requirement at 36 weeks corrected gestational age. Reintubation for a surgical procedure was not counted as an extubation failure.
The infants were monitored for adverse events during the study, including pneumothorax, hyperinflated lung fields on chest radiograph defined as >10 rib expansion, pulmonary hemorrhage and feeding intolerance defined as residuals of >50% of feeding volume.
The data were analyzed using the STATA system for statistical analysis (STATACorp LP, College Station, TX, USA). Student's t-tests and Welch's t-tests were used to compare the equivalence of continuous independent and dependent variables in the FP group to the VT group. The Fisher's exact test was used for categorical variables. Statistical significance was defined as a P-value of p0.05.
Results
In total, 42 infants qualified for the study, of which two declined to consent and one infant died while on the study, thus leaving a total of 39 infants studied. Demographics are shown in Table 2 . There was no significant difference in male sex, birth weight, gestational age at birth, weight at extubation, maternal betamethasone and surfactant use between the two groups.
The extubation failure rate in the first 72 h for the FP group was 18% whereas it was 9% for the VT group. The failure rate p7 days after extubation was 30% for the FP group and 27% for the VT group. The mean total number of days reintubated was 4±7 days for FP and 6 ± 8 days for VT. The rate of chronic lung disease defined as oxygen requirement at 36 weeks corrected gestational age was 25% for the FP group and 32% for the VT group. None of these values were statistically significant. The total average number of days on the HFNC was 29 days, FP having 33 ± 11 days and 26±12 days for VT (P>0.05). The acquisition cost of the FP HFNC is $885, whereas it is $3750 for VT HFNC, which is a difference of $2865. The operating cost of each unit for the average number of days that a patient spent on HFNC in this study (29 days) was $202 for FP and $188 for VT. 7, 8 Operating costs for the FP machine are variable depending on the number of days the patient is treated, whereas the operating cost of VT are a step function, in which costs are fixed in 30-day increments, but increase one step between 30-day increments (Table 1) .
There were no side effects noted with HFNC use, including pneumothorax, hyperinflated lung fields on chest radiograph, pulmonary hemorrhage and feeding intolerance. One infant died secondary to pseudomonas sepsis (VT group) and one infant developed necrotizing enterocolitis after HFNC therapy (FP group). The infant with pseudomonas sepsis was on VT for a total of 3 days before requiring reintubation for apnea. A blood culture that There were no significant differences between the two groups. Effectiveness of FP and VT HFNCs SM Miller and SA Dowd was obtained on VT was negative. The second blood culture obtained after the baby required reintubation grew pseudomonas aeruginosa. The circuit was not cultured. When VT was previously recalled for possible contamination with Ralstonia, it was related to the use of tap water in the unit and reuse of the cartridge, neither of which occurred in this case. Condensation buildup in the circuit, known as 'rainout', occurred in two of our patients in the FP group, in which one infant developed respiratory distress requiring reintubation.
Discussion
Humidified HFNCs have become pervasive in NICUs over the past few years. They are easy to use, well tolerated by infants and reported to be as effective as nasal CPAP. 4, 9, 10 The primary benefit of the heated humidified high flow is that the gas is heated to body temperature, which prevents heat loss and is gentle on developing lungs while providing support. The relative humidity for each device is reported to be near 100% at a temperature of 37 1C. The FP device uses a humidification chamber to create humidity, which is then further heated in the tubing to 40 1C and 85% humidity. The gas then leaves the heated wire and enters the cannula tubing, which is not heated, and hence the temperature should drop back to 37 1C and will again be near 100% humidity. An issue arises when the temperature of the infant's isolette can interfere with the circuit temperature, causing it to cool below 37 1C; condensation builds up that may cause water droplets in the circuit, rainout, and thus to the infant. 11 The VT device humidifies the gas with a cartridge system while heating to the prescribed temperature of 37 1C. It delivers the gas through a triple lumen tube, which maintains the temperature and humidification, minimizing the risk of condensation to the infant. 12 Rainout did not occur in the VT group. Of the two infants in the FP group who were noted to have rainout in their circuits, one developed respiratory distress and subsequently required reintubation. This issue deserves further study with a larger population of infants to determine whether this is a significant problem for the FP device and the consequences that rainout has, if any, on patient outcomes.
This study was undertaken shortly after the Vapotherm unit was approved for use after the voluntarily removal of the unit by the manufacturer to evaluate for possible bacterial contamination. At that time, our NICU was using both the FP and VT devices. The salient finding of this pilot study is that no differences in the primary outcome, that is, the need to reintubate within 72 h, were noted between the two devices. Moreover, secondary variables also failed to show differences, although this study was not powered to do so.
This study was limited by the inability to blind our clinicians to the treatment and mask the intervention, the lack of monitoring of distending pressure from the HFNC as well as the small sample size. On the basis of our estimates of the treatment effect size, a larger study of nearly 300 infants would be required to compare the two groups. A larger study might consider performing a cost analysis as well, considering the two devices differ in both acquisition cost and operating cost (Table 1) . 7, 8 One point highlighted in this study is the large percentage of infants born between 26 through 29 weeks who fail attempts at extubation. This group of infants was selected because they are likely to require a brief time on the ventilator initially and will require respiratory support off of the ventilator. Many studies have analyzed predicting readiness for extubation in the premature infant. [13] [14] [15] [16] The methods described often are not easily translated into clinical practice and thus are of limited utility. 13, 16 Infants in our study were electively extubated once they were clinically stable as determined by the attending neonatologist, with a mean airway pressure of p6 and an oxygen requirement of p35%. Many studies publish reintubation rates in the first 48 h, 72 h or the first 7 days after extubation, and that is why we chose to study the time points of 72 h and p7days after extubation. 17, 18 We conducted an unpublished retrospective review of the reintubation rates of 114 infants based on gestational age in our institution over the course of 2 years. We found that the overall rate of failure for infants in that retrospective review for infants born between 26 to 29 weeks was 30%. These infants were extubated to a varied level of respiratory support including CPAP, HFNC, low-flow nasal cannula (<500 ml min -1 ) or no support. Considering that the extubation failure rates are similar between the retrospective review and the current study, one might question whether the level of support matters in the extubation success or whether it is more a factor of immaturity. Although we did not measure the distending pressure delivered by the HFNC in this study, the low rate of reintubation by 7 days in both groups suggests that the HFNC generates a sufficient amount of pressure to the patient that can sustain immature lungs for at least a week. The majority of infants reintubated in this study had increasing apnea and bradycardia or a sepsis-like picture. Future studies should focus on extubation success using various modes of support such as HFNC, CPAP and low-flow nasal cannula.
To conclude, we did not find any difference between the FP and VT HFNC when analyzing extubation success of the premature infant in this pilot study. Because of the small sample size, we cannot recommend one device over the other. Future studies are necessary to further evaluate this popular new modality and help define the role it should have in the NICU.
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